Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly

J. A. Staessen, R. Fagard, L. Thijs, H. Cells, W. H. Birkenhager, C. J. Bulpitt, P. W. De Leeuw, A. E. Fletcher, M. R. Babarskiene, F. Forette, J. Kocemba, T. Laks, G. Leonetti, C. Nachev, J. C. Petrie, J. Tuomilehto, H. Vanhanen, J. Webster, Y. Yodfat, A. Zanchetti

Research output: Contribution to journalArticle

Abstract

Background: In 1989, the European Working Party on High Blood Pressure in the Elderly started the double-blind, placebo-controlled, Systolic Hypertension in Europe Trial to test the hypothesis that antihypertensive drug treatment would reduce the incidence of fatal and nonfatal stroke in older patients with isolated systolic hypertension. This report addresses whether the benefit of antihypertensive treatment varied according to sex, previous cardiovascular complications, age, initial blood pressure (BP), and smoking or drinking habits in an intention-to-treat analysis and explores whether the morbidity and mortality results were consistent in a per-protocol analysis. Methods: After stratification for center, sex, and cardiovascular complications, 4695 patients 60 years of age or older with a systolic BP of 160 to 219 mm Hg and diastolic BP less than 95 mm Hg were randomized. Active treatment consisted of nitrendipine (10-40 mg/d), with the possible addition of enalapril maleate (5-20 mg/d) and/or hydrochlorothiazide (12.5-25 mg/d), titrated or combined to reduce the sitting systolic BP by at least 20 mm Hg, to below 150 mm Hg. In the control group, matching placebo tablets were employed similarly. Results: In the intention-to-treat analysis, male sex, previous cardiovascular complications, older age, higher systolic BP, and smoking at randomization were positively and independently correlated with cardiovascular risk. Furthermore, for total (P = .009) and cardiovascular (P = .09) mortality, the benefit of antihypertensive drug treatment weakened with advancing age; for total mortality (P = .05), the benefit increased with higher systolic BP at entry, while for fatal and nonfatal stroke (P = .01), it was most evident in nonsmokers (92.5% of all patients). In the perprotocol analysis, active treatment reduced total mortality by 24% (P = .05), reduced all fatal and nonfatal cardiovascular end points by 32% (P<.001), reduced all strokes by 44% (P = .004), reduced nonfatal strokes by 48% (P = .005), and reduced all cardiac end points, including sudden death, by 26% (P = .05). Conclusions: In elderly patients with isolated systolic hypertension, stepwise antihypertensive drug treatment, starting with the dihydropyridine calcium channel blocker nitrendipine, improves prognosis. The per-protocol analysis suggested that treating 1000 patients for 5 years would prevent 24 deaths, 54 major cardiovascular end points, 29 strokes, or 25 cardiac end points. The effects of antihypertensive drug treatment on total and cardiovascular mortality may be attenuated in very old patients.

Original languageEnglish
Pages (from-to)1681-1691
Number of pages11
JournalArchives of Internal Medicine
Volume158
Issue number15
DOIs
Publication statusPublished - Aug 24 1998

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly'. Together they form a unique fingerprint.

  • Cite this

    Staessen, J. A., Fagard, R., Thijs, L., Cells, H., Birkenhager, W. H., Bulpitt, C. J., De Leeuw, P. W., Fletcher, A. E., Babarskiene, M. R., Forette, F., Kocemba, J., Laks, T., Leonetti, G., Nachev, C., Petrie, J. C., Tuomilehto, J., Vanhanen, H., Webster, J., Yodfat, Y., & Zanchetti, A. (1998). Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal Medicine, 158(15), 1681-1691. https://doi.org/10.1001/archinte.158.15.1681